Results

Total Results: 835 records

Showing results for "format".

441. Disposition of Comments for Management of Suspected Opioid Overdose With Naloxone by Emergency Medical Services Personnel (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-193-disposition-comments-naloxone.pdf
     November 27, 2017 - AHRQ format uses the appendixes label rather than appendices. … Twitter is a social media platform that promotes concise information sharing in a peer to peer format … Reviewer #2 Results The key characteristics of the studies are summarized in an easily comparable format

442. Enhanced Functionality for the Distributed Research Network Pilot (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/distributed-network-expansion_research.pdf
     April 01, 2012 - Validation of Local Data Marts DRN 1.5 assumes that the underlying data is in the correct format. … table has the appropriate column setup; and (c) Data in each of the table rows match the expected format

443. Disposition of Comments Report for Pressure Ulcer Risk Assessment and Prevention (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/pressure-ulcer-prevention_disposition-comments.pdf
     May 08, 2013 - Our Analytic Framework follows the typical format/structure as these tools are currently utilized and

444. PowerPoint Presentation (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/medical-test-reviews-intro.ppt
     June 01, 2012 - Preventive Services Task Force, the purpose of analytic frameworks is to present clearly in graphical format

445. Template for Reports Developed (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-updates_methods.pdf
     July 01, 2011 - Currently, the SCEPC is developing the recommended format of the summary table.

446. PowerPoint Presentation (ppt file)
     effectivehealthcare.ahrq.gov/sites/default/files/medical-test-reviews-intro.ppt
     June 01, 2012 - Preventive Services Task Force, the purpose of analytic frameworks is to present clearly in graphical format

447. Interventions Targeting Sensory Challenges in Children With Autism Spectrum Disorders - An Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/asd-interventions-disposition.pdf
     May 26, 2017 - areas of interest to me, and then to go back and review the entire manuscript in a more chronologic format

448. Disposition of Comments Report for Local Therapies for Unresectable Primary Hepatocellular Carcinoma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/liver-cancer-therapy_disposition-comments.pdf
     May 24, 2013 - Disposition of Comments Report for Local Therapies for Unresectable Primary Hepatocellular Carcinoma Comparative Effectiveness Research Review Disposition of Comments Report Research Review Title: Local Therapies for Unresectable Primary Hepatocellular Carcinoma Draft review available for public comme…

449. S158 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s158.pdf
     October 01, 2007 - ORIGINAL ARTICLE Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information Til Stürmer, MD,*† Robert J. Glynn, PhD,*†‡ Kenneth J. Rothman, DrPH,*§¶ Jerry Avorn, MD,* and Sebastian Schneeweiss, MD*� Background: Nonexperimental studies of drug effects in large automa…

450. Methods Guide for Medical Test Reviews Chapter 7 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-grading_methods.pdf
     July 01, 2012 - However, for diagnostic test performance reviews, the most common presentation format is a summary receiver

451. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/atypical-antipsychotics-off-label_executive.pdf
     January 01, 2007 - Layout 1 Background Aripiprazole, olanzapine, quetiapine, risperidone, and ziprasidone are atypical antipsychotics approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia and bipolar disorder. These drugs have been studied for off-label use in the following conditions: dementia and seve…

452. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/musculoskeletal-complaints-tests-children_research-protocol.pdf
     September 29, 2010 - Evidence-based Practice Center Systematic Review Protocol Source: www.effectivehealthcare.ahrq.gov Published Online: September 29, 2010 Evidence-based Practice Center Systematic Review Protocol Project Title: Antinuclear Antibody, Rheumatoid Factor, and Cyclic- Citrullinated Peptide Testing for the Eva…

453. Disposition of Comments Report for Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/asthma-immunotherapy-2010_disposition-comments.pdf
     January 01, 2010 - Disposition of Comments Report for Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and/or Asthma Comparative Effectiveness Research Review Disposition of Comments Report Research Review Title: Allergen-Specific Immunotherapy for the Treatment of Allergic Rhinoconjunctivit…

454. Disposition of Comments Report for Interventions To Modify Health Care Provider Adherence to Asthma Guidelines (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/asthma-provider-adherence_disposition-comments.pdf
     May 19, 2013 - TEP #2 Discussion/ Conclusion The conclusions are not stated in the same format for all issues.

455. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-cholestorol-medications_executive.pdf
     September 01, 2009 - Layout 1 Background Over 28 million Americans have some form of cardiovascular disease (CVD), which causes more deaths than cancer, diabetes, accidents, and chronic lung diseases combined. Estimated direct medical expenditures and lost productivity from CVD amounted to $431.8 billion in the United States in 2007. …

456. The Role of Immunotherapy and the Management of Asthma: Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/asthma-immunotherapy_research-protocol.pdf
     September 14, 2016 - The search strategy, in PubMed format is: (immunotherapy[mesh] OR immunotherap*[tiab]) AND (asthma[

457. Guidance for the Conduct and Reporting of Modeling and Simulation Studies in the Context of Health Technology Assessment (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/decision-models-guidance_methods.pdf
     October 01, 2016 - Reporting format for economic evaluation. Part II: Focus on modelling studies. … The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation

458. Disposition of Comments Report for Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/antiplatelet-treatment_disposition-comments.pdf
     September 25, 2013 - Disposition of Comments Report for Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment Comparative Effectiveness Review Disposition of Comments Report Research Review Title: Testing of CYP2C19 Variants and Platelet Reactivity for Guiding Antiplatelet Treatment Draft …

459. Disposition of Comments Report for Treatments for Ankyloglossia and Ankyloglossia With Concomitant Lip-Tie (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/ankyloglossia_disposition-comments.pdf
     May 04, 2015 - This is the standard format for the analytic framework. See: Helfand M, Balshem H.

460. Glaucoma-Screening Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/glaucoma-screening_executive.pdf
     April 01, 2012 - 1 Comparative Effectiveness Review Number 59 Screening for Glaucoma: Comparative Effectiveness Executive Summary Background Glaucoma is a leading cause of visual impairment and blindness and affects approximately 60.5 million people worldwide.1,2 Although glaucoma may be characterized by optic nerve damage, …